{"gene":"POLE2","run_date":"2026-04-28T19:45:44","timeline":{"discoveries":[{"year":2002,"finding":"The second largest subunit of mouse DNA polymerase epsilon (DPE2/POLE2) interacts with SAP18 (a polypeptide associated with co-repressor Sin3) via its N-terminal region (amino acids 85-250), and this interaction recruits histone deacetylase (HDAC) activity to repress transcription, as shown by reporter assays inhibited by trichostatin A.","method":"Yeast two-hybrid screening, co-immunoprecipitation, reporter plasmid assays, trichostatin A inhibition","journal":"Journal of biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 — reciprocal interaction mapped to defined domain, functional transcriptional repression assay; single lab","pmids":["11872158"],"is_preprint":false},{"year":2001,"finding":"The human POLE2 promoter contains an Sp1 element critical for basal activity and two overlapping E2F elements essential for full promoter activity and serum response; E2F1 and NF-1 binding sites reside downstream, and POLE2 expression is regulated by two E2F-pocket protein complexes (one with Sp1, one with NF-1), linking POLE2 transcription to the cell cycle.","method":"Luciferase reporter assay, electrophoretic mobility shift assay (EMSA), DNase I footprinting","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal biochemical methods (reporter, EMSA, footprinting) in single study with rigorous controls","pmids":["11433027"],"is_preprint":false},{"year":2022,"finding":"POLE2 knockdown in glioblastoma cells promotes ubiquitination and reduces stability of FOXM1 via Aurora kinase A (AURKA); knockdown of FOXM1 weakens the pro-tumorigenic effects of POLE2, placing POLE2 upstream of AURKA-mediated FOXM1 stabilization.","method":"Loss-of-function (shRNA knockdown), ubiquitination assay, rescue experiments with FOXM1 knockdown, in vitro and in vivo tumor assays","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2-3 — epistasis established by rescue experiment; single lab, multiple functional readouts","pmids":["35039475"],"is_preprint":false},{"year":2021,"finding":"POLE2 knockdown in renal cell carcinoma cells identified stanniocalcin 1 (STC1) as a downstream gene of POLE2; co-immunoprecipitation and microarray analyses established that POLE2 regulates STC1 to promote RCC proliferation and migration.","method":"Co-immunoprecipitation, microarray, rescue experiment, Western blot, in vitro and in vivo tumor assays","journal":"Frontiers in cell and developmental biology","confidence":"Medium","confidence_rationale":"Tier 2-3 — Co-IP and rescue experiment support pathway placement; single lab","pmids":["33644060"],"is_preprint":false},{"year":2024,"finding":"POLE2 promotes osteosarcoma progression by reducing MDM2-mediated ubiquitination and degradation of CD44, thereby stabilizing CD44 and activating the Rac signaling pathway; knockdown of CD44 reversed the tumor-promoting effects of POLE2 overexpression.","method":"Ubiquitination assay, bioinformatics, Western blot, rescue experiments with CD44 knockdown, in vitro and in vivo tumor assays","journal":"Cell death discovery","confidence":"Medium","confidence_rationale":"Tier 2-3 — ubiquitination assay and rescue epistasis; single lab","pmids":["38627379"],"is_preprint":false},{"year":2023,"finding":"POLE2 overexpression in gastric cancer cells elevates NRF2 expression and activity, which subsequently activates GPX4 to prevent lipid peroxidation and ferroptosis; silencing NRF2 or GPX4 reversed POLE2 overexpression-mediated cell survival, establishing the POLE2→NRF2→GPX4 pathway.","method":"Lentiviral overexpression and knockdown, ferroptosis assays (lipid peroxidation, cell viability), rescue experiments with NRF2/GPX4 silencing, Western blot","journal":"Journal of cellular and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2-3 — pathway placed by rescue epistasis; single lab, multiple functional readouts","pmids":["38070189"],"is_preprint":false},{"year":2023,"finding":"HDAC10 deacetylates SP1; HDAC10 knockdown increases SP1 acetylation, which inhibits SP1 binding to the POLE2 promoter and reduces POLE2 expression, thereby impairing DNA damage repair in NSCLC cells; overexpression of SP1 or POLE2 partially rescued effects of HDAC10 loss.","method":"shRNA knockdown, acetylation assay, ChIP/promoter binding assay, overexpression rescue, Western blot, DNA damage assays","journal":"Pulmonary pharmacology & therapeutics","confidence":"Medium","confidence_rationale":"Tier 2 — mechanism includes post-translational modification (acetylation) and promoter binding; single lab with multiple methods","pmids":["37657752"],"is_preprint":false},{"year":2022,"finding":"The transcription factor FOXM1 directly regulates POLE2 expression in lung adenocarcinoma; berberine treatment downregulates FOXM1, which in turn reduces POLE2 expression, and FOXM1 acts as a molecular bridge between berberine and POLE2.","method":"Plasmid transfection (FOXM1 overexpression/knockdown), qRT-PCR, Western blot, in vitro and in vivo proliferation assays","journal":"Frontiers in pharmacology","confidence":"Medium","confidence_rationale":"Tier 3 — FOXM1→POLE2 transcriptional axis shown by overexpression/knockdown; single lab","pmids":["35173608"],"is_preprint":false},{"year":2025,"finding":"POLE2 functions as a general NPF-motif receptor: its C-terminal shallow pocket (residues Y513, E520, S522) selectively binds diverse NPF-containing peptides including SYNJ1, WDHD1, DONSON, and TTF2, as demonstrated by quantitative native holdup assay, biochemical affinity measurements, mutational analysis, and AlphaFold structural predictions; motif mutations abolish binding in cell extracts.","method":"Native holdup assay, quantitative binding measurements, mutational analysis (Y513, E520, S522), AlphaFold structural prediction, proteome-scale affinity screen, cell extract binding assays","journal":"bioRxiv","confidence":"High","confidence_rationale":"Tier 1-2 — reconstituted binding assay with mutagenesis and structural validation, multiple orthogonal methods in one study","pmids":["bio_10.1101_2025.03.17.643635"],"is_preprint":true},{"year":2024,"finding":"TTF2 couples the TRAIP ubiquitin ligase to DNA Polymerase ε (Polε) during mitosis via: (1) tandem Zinc fingers in TTF2 that recognize phosphorylated TRAIP, and (2) a TTF2 motif that directly binds POLE2; this tripartite complex causes TRAIP to ubiquitylate the CMG helicase, triggering mitotic replisome disassembly and MiDAS.","method":"Biochemical reconstitution, co-immunoprecipitation, domain mapping (zinc finger mutants, POLE2-binding motif mutants), ubiquitylation assay, mitotic replisome disassembly assay","journal":"bioRxiv","confidence":"High","confidence_rationale":"Tier 1-2 — reconstituted complex with domain mapping and functional ubiquitylation assay; multiple orthogonal approaches in one study","pmids":["bio_10.1101_2024.12.01.626218"],"is_preprint":true},{"year":2025,"finding":"GINS4 directly binds POLE2 (predicted by STRING/HDOCK databases and supported by experimental validation); GINS4 knockdown reduces POLE2 expression and inhibits PI3K/AKT signaling via POLE2; POLE2 overexpression reverses the effects of GINS4 silencing on HCC cell proliferation, cycle arrest, and ferroptosis.","method":"Co-immunoprecipitation (interaction prediction + experimental), lentiviral knockdown/overexpression, Western blot, flow cytometry, xenograft model","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2-3 — binding interaction and rescue epistasis; computational prediction validated experimentally; single lab","pmids":["40081544"],"is_preprint":false},{"year":2026,"finding":"POLE2 acts upstream of GINS1 in renal cell carcinoma; GINS1 overexpression reverses the inhibitory effects of POLE2 knockdown on proliferation, metastasis, EMT, and autophagy suppression; the POLE2/GINS1 axis inhibits AKT/mTOR-mediated autophagy to promote EMT and lung metastasis.","method":"Bioinformatics, lentiviral knockdown/overexpression, rescue experiments, in vitro and in vivo models, Western blot","journal":"Apoptosis","confidence":"Medium","confidence_rationale":"Tier 2-3 — pathway epistasis established by rescue; single lab with in vivo validation","pmids":["41893924"],"is_preprint":false}],"current_model":"POLE2 (the non-catalytic B-subunit of human DNA polymerase ε) serves as a structural and interaction hub at the replication fork: its C-terminal domain acts as an NPF-motif receptor that recruits diverse nuclear partners (including TTF2, WDHD1, DONSON) involved in replication, DNA repair, and transcription regulation; its N-terminal region binds SAP18 to recruit the Sin3/HDAC co-repressor for chromatin remodeling; during mitosis, TTF2 bridges TRAIP to POLE2, directing TRAIP-mediated ubiquitylation of the CMG helicase to trigger replisome disassembly and MiDAS; its transcription is controlled by an Sp1/E2F promoter element and modulated upstream by FOXM1 and the HDAC10/SP1 acetylation axis; in cancer cells, POLE2 promotes proliferation through downstream stabilization of CD44 (via MDM2 inhibition), FOXM1 (via AURKA), and activation of NRF2/GPX4, PI3K/AKT, and Wnt/β-catenin signaling pathways."},"narrative":{"teleology":[{"year":2001,"claim":"Establishing how POLE2 transcription is cell-cycle regulated resolved the question of how a replication gene is coordinately expressed during S phase: the POLE2 promoter requires an Sp1 element for basal activity and two overlapping E2F sites for full serum-responsive induction, linking POLE2 expression to E2F-pocket protein complexes.","evidence":"Luciferase reporter assays, EMSA, and DNase I footprinting of the human POLE2 promoter","pmids":["11433027"],"confidence":"High","gaps":["Whether E2F-mediated regulation is sufficient to explain POLE2 expression in all cell types","No chromatin-level (ChIP) confirmation of E2F occupancy in vivo at the time"]},{"year":2002,"claim":"Demonstrating that POLE2's N-terminal region binds SAP18 and recruits HDAC activity revealed a non-replicative, transcription-regulatory function for a polymerase subunit, expanding the functional repertoire of replication machinery components.","evidence":"Yeast two-hybrid, co-immunoprecipitation, reporter assays with trichostatin A inhibition in mouse system","pmids":["11872158"],"confidence":"Medium","gaps":["Interaction demonstrated in mouse; not confirmed in human cells","Endogenous target genes repressed by the POLE2–SAP18–Sin3/HDAC complex remain unidentified","No structural detail of the N-terminal SAP18-binding interface"]},{"year":2022,"claim":"Placing POLE2 upstream of AURKA-mediated FOXM1 stabilization in glioblastoma established the first cancer-associated signaling axis through which POLE2 promotes tumor growth beyond its replicative role.","evidence":"shRNA knockdown, ubiquitination assays, and rescue experiments in glioblastoma cells in vitro and in vivo","pmids":["35039475"],"confidence":"Medium","gaps":["Mechanism by which POLE2 influences AURKA activity is unknown","Not replicated outside glioblastoma"]},{"year":2022,"claim":"Identifying FOXM1 as a direct transcriptional regulator of POLE2 expression created a potential FOXM1→POLE2→AURKA→FOXM1 feedback loop, though these findings come from separate cancer types.","evidence":"FOXM1 overexpression/knockdown with qRT-PCR and Western blot in lung adenocarcinoma cells","pmids":["35173608"],"confidence":"Medium","gaps":["Direct promoter binding by FOXM1 not shown by ChIP","Whether a true feedback loop operates in any single cell type is untested"]},{"year":2023,"claim":"Demonstrating that HDAC10 deacetylates SP1 to maintain SP1 binding at the POLE2 promoter connected epigenetic regulation to POLE2 expression and DNA damage repair, providing an upstream regulatory layer.","evidence":"shRNA knockdown, acetylation assay, ChIP, overexpression rescue, DNA damage assays in NSCLC cells","pmids":["37657752"],"confidence":"Medium","gaps":["Whether SP1 acetylation status affects POLE2 expression in non-cancer contexts is unknown","Specific acetylation sites on SP1 not mapped"]},{"year":2023,"claim":"Showing that POLE2 activates NRF2/GPX4 signaling to suppress ferroptosis in gastric cancer revealed a non-canonical role for POLE2 in regulating oxidative stress and cell death.","evidence":"Overexpression/knockdown, ferroptosis assays, rescue with NRF2/GPX4 silencing in gastric cancer cells","pmids":["38070189"],"confidence":"Medium","gaps":["How POLE2, a replication factor, mechanistically upregulates NRF2 transcription or stability is unresolved","Single cancer type; no normal-tissue comparison"]},{"year":2024,"claim":"Establishing that POLE2 stabilizes CD44 by reducing MDM2-mediated ubiquitination linked POLE2 to Rac signaling and osteosarcoma progression, showing POLE2 can modulate specific E3 ligase–substrate interactions.","evidence":"Ubiquitination assay, rescue epistasis with CD44 knockdown, in vitro and in vivo osteosarcoma models","pmids":["38627379"],"confidence":"Medium","gaps":["Whether POLE2 directly interacts with MDM2 or CD44, or acts indirectly, is undetermined","Mechanism of MDM2 inhibition by POLE2 not established"]},{"year":2024,"claim":"Reconstitution of the TTF2–TRAIP–POLE2 tripartite complex during mitosis answered how the TRAIP ubiquitin ligase is targeted to the replisome: TTF2 bridges phosphorylated TRAIP to POLE2, directing CMG helicase ubiquitylation for replisome disassembly and MiDAS.","evidence":"Biochemical reconstitution, domain mapping with zinc-finger and POLE2-binding-motif mutants, ubiquitylation assay (preprint)","pmids":["bio_10.1101_2024.12.01.626218"],"confidence":"High","gaps":["Awaits peer-reviewed publication","In vivo validation of TTF2-POLE2 interaction requirements for MiDAS not yet shown in mammalian cells","Whether other NPF-containing partners compete with TTF2 for POLE2 binding during mitosis is unknown"]},{"year":2025,"claim":"Identifying POLE2's C-terminal pocket as a general NPF-motif receptor that binds multiple nuclear partners (TTF2, WDHD1, DONSON, SYNJ1) resolved the structural basis of POLE2's role as a protein-interaction hub at the replication fork.","evidence":"Native holdup assay, quantitative binding measurements, mutagenesis of Y513/E520/S522, AlphaFold modeling, proteome-scale screen (preprint)","pmids":["bio_10.1101_2025.03.17.643635"],"confidence":"High","gaps":["Awaits peer-reviewed publication","Crystal or cryo-EM structure of the NPF-POLE2 complex not yet available","Functional consequences of individual NPF-partner recruitment at the fork remain to be dissected"]},{"year":2025,"claim":"Demonstrating that GINS4 binds POLE2 and signals through PI3K/AKT extended the replication-complex interactome of POLE2 and linked it to a growth-signaling pathway in hepatocellular carcinoma.","evidence":"Co-immunoprecipitation, lentiviral knockdown/overexpression rescue, Western blot, xenograft model in HCC","pmids":["40081544"],"confidence":"Medium","gaps":["GINS4–POLE2 interaction initially predicted computationally; single reciprocal Co-IP","Whether PI3K/AKT activation is a direct or indirect consequence of the GINS4–POLE2 axis is unknown"]},{"year":null,"claim":"Key unresolved questions include how POLE2's NPF-motif receptor function is regulated during the cell cycle (partner switching), how POLE2 influences signaling pathways (NRF2, PI3K/AKT, Wnt) outside its replication role, and whether the non-replicative cancer phenotypes reflect physiological functions or neomorphic activities.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural determination of the full-length POLE2 in complex with Pol ε holoenzyme and NPF partners","Mechanism connecting POLE2 to transcription factor or E3 ligase regulation remains indirect in all cancer studies","Whether POLE2's NPF-binding and SAP18-binding functions are coordinated or mutually exclusive is untested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[8,9]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[8,9]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,8,9]}],"pathway":[{"term_id":"R-HSA-69306","term_label":"DNA Replication","supporting_discovery_ids":[8,9]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[1,9]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[6]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[0]}],"complexes":["DNA polymerase ε holoenzyme","TTF2–TRAIP–POLE2 complex","SAP18–Sin3/HDAC complex"],"partners":["SAP18","TTF2","TRAIP","WDHD1","DONSON","GINS4","FOXM1"],"other_free_text":[]},"mechanistic_narrative":"POLE2 encodes the non-catalytic B-subunit of DNA polymerase ε, functioning as a structural scaffold and protein-interaction hub at the replication fork whose transcription is cell-cycle regulated through Sp1/E2F promoter elements and modulated by the HDAC10/SP1 acetylation axis and FOXM1 [PMID:11433027, PMID:37657752, PMID:35173608]. Its C-terminal domain acts as a general NPF-motif receptor that recruits diverse nuclear partners—including TTF2, WDHD1, and DONSON—through a shallow binding pocket defined by residues Y513, E520, and S522, while its N-terminal region binds SAP18 to recruit Sin3/HDAC co-repressor activity for transcriptional repression [PMID:11872158, PMID:bio_10.1101_2025.03.17.643635]. During mitosis, TTF2 bridges TRAIP to POLE2, directing TRAIP-mediated ubiquitylation of the CMG helicase to trigger replisome disassembly and mitosis-specific DNA synthesis (MiDAS) [PMID:bio_10.1101_2024.12.01.626218]. In cancer contexts, POLE2 promotes proliferation through stabilization of FOXM1 via AURKA and of CD44 via MDM2 inhibition, and activates NRF2/GPX4-mediated ferroptosis resistance and PI3K/AKT signaling [PMID:35039475, PMID:38627379, PMID:38070189, PMID:40081544]."},"prefetch_data":{"uniprot":{"accession":"P56282","full_name":"DNA polymerase epsilon subunit 2","aliases":["DNA polymerase II subunit 2","DNA polymerase epsilon subunit B"],"length_aa":527,"mass_kda":59.5,"function":"Accessory component of the DNA polymerase epsilon complex (PubMed:10801849). Participates in DNA repair and in chromosomal DNA replication (By similarity)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/P56282/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/POLE2","classification":"Common Essential","n_dependent_lines":1204,"n_total_lines":1208,"dependency_fraction":0.9966887417218543},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/POLE2","total_profiled":1310},"omim":[{"mim_id":"608684","title":"NINEIN; NIN","url":"https://www.omim.org/entry/608684"},{"mim_id":"607269","title":"POLYMERASE, DNA, EPSILON-4; POLE4","url":"https://www.omim.org/entry/607269"},{"mim_id":"607267","title":"POLYMERASE, DNA, EPSILON-3; POLE3","url":"https://www.omim.org/entry/607267"},{"mim_id":"602670","title":"POLYMERASE, DNA, EPSILON-2; POLE2","url":"https://www.omim.org/entry/602670"},{"mim_id":"174762","title":"POLYMERASE, DNA, EPSILON; POLE","url":"https://www.omim.org/entry/174762"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Nuclear bodies","reliability":"Supported"},{"location":"Vesicles","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"bone marrow","ntpm":17.3}],"url":"https://www.proteinatlas.org/search/POLE2"},"hgnc":{"alias_symbol":["DPE2"],"prev_symbol":[]},"alphafold":{"accession":"P56282","domains":[{"cath_id":"1.10.8.60","chopping":"4-78","consensus_level":"high","plddt":86.4535,"start":4,"end":78}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P56282","model_url":"https://alphafold.ebi.ac.uk/files/AF-P56282-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P56282-F1-predicted_aligned_error_v6.png","plddt_mean":93.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=POLE2","jax_strain_url":"https://www.jax.org/strain/search?query=POLE2"},"sequence":{"accession":"P56282","fasta_url":"https://rest.uniprot.org/uniprotkb/P56282.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P56282/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P56282"}},"corpus_meta":[{"pmid":"30132567","id":"PMC_30132567","title":"Knockdown of POLE2 expression suppresses lung adenocarcinoma cell malignant phenotypes in vitro.","date":"2018","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/30132567","citation_count":28,"is_preprint":false},{"pmid":"29155859","id":"PMC_29155859","title":"Reduced starch granule number per chloroplast in the dpe2/phs1 mutant is dependent on initiation of starch degradation.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/29155859","citation_count":21,"is_preprint":false},{"pmid":"35039475","id":"PMC_35039475","title":"POLE2 facilitates the malignant phenotypes of glioblastoma through promoting AURKA-mediated stabilization of FOXM1.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/35039475","citation_count":20,"is_preprint":false},{"pmid":"32831648","id":"PMC_32831648","title":"POLE2 knockdown reduce tumorigenesis in esophageal squamous cells.","date":"2020","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/32831648","citation_count":20,"is_preprint":false},{"pmid":"26006747","id":"PMC_26006747","title":"In silico analysis of family GH77 with focus on amylomaltases from borreliae and disproportionating enzymes DPE2 from plants and bacteria.","date":"2015","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/26006747","citation_count":18,"is_preprint":false},{"pmid":"11433027","id":"PMC_11433027","title":"E2F mediates induction of the Sp1-controlled promoter of the human DNA polymerase epsilon B-subunit gene POLE2.","date":"2001","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/11433027","citation_count":16,"is_preprint":false},{"pmid":"11872158","id":"PMC_11872158","title":"The second largest subunit of mouse DNA polymerase epsilon, DPE2, interacts with SAP18 and recruits the Sin3 co-repressor protein to DNA.","date":"2002","source":"Journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11872158","citation_count":16,"is_preprint":false},{"pmid":"33644060","id":"PMC_33644060","title":"Targeting POLE2 Creates a Novel Vulnerability in Renal Cell Carcinoma via Modulating Stanniocalcin 1.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/33644060","citation_count":12,"is_preprint":false},{"pmid":"37657752","id":"PMC_37657752","title":"Knockdown of HDAC10 inhibits POLE2-mediated DNA damage repair in NSCLC cells by increasing SP1 acetylation levels.","date":"2023","source":"Pulmonary pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/37657752","citation_count":11,"is_preprint":false},{"pmid":"35173608","id":"PMC_35173608","title":"Berberine Inhibits FOXM1 Dependent Transcriptional Regulation of POLE2 and Interferes With the Survival of Lung Adenocarcinoma.","date":"2022","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35173608","citation_count":10,"is_preprint":false},{"pmid":"36407636","id":"PMC_36407636","title":"Dpe2/phs1 revealed unique starch metabolism with three distinct phases characterized by different starch granule numbers per chloroplast, allowing insights into the control mechanism of granule number regulation by gene co-regulation and metabolic profiling.","date":"2022","source":"Frontiers in plant science","url":"https://pubmed.ncbi.nlm.nih.gov/36407636","citation_count":9,"is_preprint":false},{"pmid":"38070189","id":"PMC_38070189","title":"Inhibition of ferroptosis by POLE2 in gastric cancer cells involves the activation of NRF2/GPX4 pathway.","date":"2023","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38070189","citation_count":9,"is_preprint":false},{"pmid":"28576440","id":"PMC_28576440","title":"Photometric assay of maltose and maltose-forming enzyme activity by using 4-alpha-glucanotransferase (DPE2) from higher plants.","date":"2017","source":"Analytical biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28576440","citation_count":7,"is_preprint":false},{"pmid":"36335878","id":"PMC_36335878","title":"Phosphorylation of DPE2 at S786 partially regulates starch degradation.","date":"2022","source":"Plant physiology and biochemistry : PPB","url":"https://pubmed.ncbi.nlm.nih.gov/36335878","citation_count":5,"is_preprint":false},{"pmid":"38627379","id":"PMC_38627379","title":"POLE2 promotes osteosarcoma progression by enhancing the stability of CD44.","date":"2024","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/38627379","citation_count":5,"is_preprint":false},{"pmid":"39155507","id":"PMC_39155507","title":"POLE2 silencing inhibits the progression of colorectal carcinoma cells via wnt signaling axis.","date":"2024","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/39155507","citation_count":5,"is_preprint":false},{"pmid":"38079056","id":"PMC_38079056","title":"POLE2 Regulates Apoptosis of Oral Squamous Cell Carcinoma Cells through the PI3K/AKT Signaling Pathway.","date":"2023","source":"Current medical science","url":"https://pubmed.ncbi.nlm.nih.gov/38079056","citation_count":4,"is_preprint":false},{"pmid":"35378390","id":"PMC_35378390","title":"Carbon pathways during transitory starch degradation in Arabidopsis differentially affect the starch granule number and morphology in the dpe2/phs1 mutant background.","date":"2022","source":"Plant physiology and biochemistry : PPB","url":"https://pubmed.ncbi.nlm.nih.gov/35378390","citation_count":4,"is_preprint":false},{"pmid":"40081544","id":"PMC_40081544","title":"GINS4 silencing mediates hepatocellular cancer cell proliferation, cycle and ferroptosis through POLE2.","date":"2025","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/40081544","citation_count":3,"is_preprint":false},{"pmid":"37097331","id":"PMC_37097331","title":"POLE2 knockdown suppresses lymphoma progression via downregulating Wnt/β-catenin signaling pathway.","date":"2023","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/37097331","citation_count":2,"is_preprint":false},{"pmid":"37733085","id":"PMC_37733085","title":"Silencing POLE2 promotes apoptosis and inhibits proliferation of oral squamous cell carcinomas by inhibiting PI3K/AKT signaling pathway.","date":"2023","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/37733085","citation_count":1,"is_preprint":false},{"pmid":"41893924","id":"PMC_41893924","title":"Role of POLE2/GINS1-mediated AKT/mTOR pathway in RCC autophagy, proliferation, and metastasis: evidences from bioinformatic, clinical, and experimental data.","date":"2026","source":"Apoptosis : an international journal on programmed cell death","url":"https://pubmed.ncbi.nlm.nih.gov/41893924","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.03.17.643635","title":"The non-catalytic ε DNA polymerase subunit is an NPF motif recognition protein","date":"2025-03-17","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.17.643635","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.12.01.626218","title":"TTF2 drives mitotic replisome disassembly and MiDAS by coupling the TRAIP ubiquitin ligase to Polε","date":"2024-12-02","source":"bioRxiv","url":"https://doi.org/10.1101/2024.12.01.626218","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":13243,"output_tokens":3094,"usd":0.043069},"stage2":{"model":"claude-opus-4-6","input_tokens":6460,"output_tokens":3078,"usd":0.163875},"total_usd":0.206944,"stage1_batch_id":"msgbatch_01SUR8NDzVrNmyszWyJeCct7","stage2_batch_id":"msgbatch_01G7Yfutko3cDWzejrwH5AMx","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2002,\n      \"finding\": \"The second largest subunit of mouse DNA polymerase epsilon (DPE2/POLE2) interacts with SAP18 (a polypeptide associated with co-repressor Sin3) via its N-terminal region (amino acids 85-250), and this interaction recruits histone deacetylase (HDAC) activity to repress transcription, as shown by reporter assays inhibited by trichostatin A.\",\n      \"method\": \"Yeast two-hybrid screening, co-immunoprecipitation, reporter plasmid assays, trichostatin A inhibition\",\n      \"journal\": \"Journal of biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal interaction mapped to defined domain, functional transcriptional repression assay; single lab\",\n      \"pmids\": [\"11872158\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"The human POLE2 promoter contains an Sp1 element critical for basal activity and two overlapping E2F elements essential for full promoter activity and serum response; E2F1 and NF-1 binding sites reside downstream, and POLE2 expression is regulated by two E2F-pocket protein complexes (one with Sp1, one with NF-1), linking POLE2 transcription to the cell cycle.\",\n      \"method\": \"Luciferase reporter assay, electrophoretic mobility shift assay (EMSA), DNase I footprinting\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal biochemical methods (reporter, EMSA, footprinting) in single study with rigorous controls\",\n      \"pmids\": [\"11433027\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"POLE2 knockdown in glioblastoma cells promotes ubiquitination and reduces stability of FOXM1 via Aurora kinase A (AURKA); knockdown of FOXM1 weakens the pro-tumorigenic effects of POLE2, placing POLE2 upstream of AURKA-mediated FOXM1 stabilization.\",\n      \"method\": \"Loss-of-function (shRNA knockdown), ubiquitination assay, rescue experiments with FOXM1 knockdown, in vitro and in vivo tumor assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — epistasis established by rescue experiment; single lab, multiple functional readouts\",\n      \"pmids\": [\"35039475\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"POLE2 knockdown in renal cell carcinoma cells identified stanniocalcin 1 (STC1) as a downstream gene of POLE2; co-immunoprecipitation and microarray analyses established that POLE2 regulates STC1 to promote RCC proliferation and migration.\",\n      \"method\": \"Co-immunoprecipitation, microarray, rescue experiment, Western blot, in vitro and in vivo tumor assays\",\n      \"journal\": \"Frontiers in cell and developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — Co-IP and rescue experiment support pathway placement; single lab\",\n      \"pmids\": [\"33644060\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"POLE2 promotes osteosarcoma progression by reducing MDM2-mediated ubiquitination and degradation of CD44, thereby stabilizing CD44 and activating the Rac signaling pathway; knockdown of CD44 reversed the tumor-promoting effects of POLE2 overexpression.\",\n      \"method\": \"Ubiquitination assay, bioinformatics, Western blot, rescue experiments with CD44 knockdown, in vitro and in vivo tumor assays\",\n      \"journal\": \"Cell death discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — ubiquitination assay and rescue epistasis; single lab\",\n      \"pmids\": [\"38627379\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"POLE2 overexpression in gastric cancer cells elevates NRF2 expression and activity, which subsequently activates GPX4 to prevent lipid peroxidation and ferroptosis; silencing NRF2 or GPX4 reversed POLE2 overexpression-mediated cell survival, establishing the POLE2→NRF2→GPX4 pathway.\",\n      \"method\": \"Lentiviral overexpression and knockdown, ferroptosis assays (lipid peroxidation, cell viability), rescue experiments with NRF2/GPX4 silencing, Western blot\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — pathway placed by rescue epistasis; single lab, multiple functional readouts\",\n      \"pmids\": [\"38070189\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"HDAC10 deacetylates SP1; HDAC10 knockdown increases SP1 acetylation, which inhibits SP1 binding to the POLE2 promoter and reduces POLE2 expression, thereby impairing DNA damage repair in NSCLC cells; overexpression of SP1 or POLE2 partially rescued effects of HDAC10 loss.\",\n      \"method\": \"shRNA knockdown, acetylation assay, ChIP/promoter binding assay, overexpression rescue, Western blot, DNA damage assays\",\n      \"journal\": \"Pulmonary pharmacology & therapeutics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanism includes post-translational modification (acetylation) and promoter binding; single lab with multiple methods\",\n      \"pmids\": [\"37657752\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The transcription factor FOXM1 directly regulates POLE2 expression in lung adenocarcinoma; berberine treatment downregulates FOXM1, which in turn reduces POLE2 expression, and FOXM1 acts as a molecular bridge between berberine and POLE2.\",\n      \"method\": \"Plasmid transfection (FOXM1 overexpression/knockdown), qRT-PCR, Western blot, in vitro and in vivo proliferation assays\",\n      \"journal\": \"Frontiers in pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — FOXM1→POLE2 transcriptional axis shown by overexpression/knockdown; single lab\",\n      \"pmids\": [\"35173608\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"POLE2 functions as a general NPF-motif receptor: its C-terminal shallow pocket (residues Y513, E520, S522) selectively binds diverse NPF-containing peptides including SYNJ1, WDHD1, DONSON, and TTF2, as demonstrated by quantitative native holdup assay, biochemical affinity measurements, mutational analysis, and AlphaFold structural predictions; motif mutations abolish binding in cell extracts.\",\n      \"method\": \"Native holdup assay, quantitative binding measurements, mutational analysis (Y513, E520, S522), AlphaFold structural prediction, proteome-scale affinity screen, cell extract binding assays\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reconstituted binding assay with mutagenesis and structural validation, multiple orthogonal methods in one study\",\n      \"pmids\": [\"bio_10.1101_2025.03.17.643635\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TTF2 couples the TRAIP ubiquitin ligase to DNA Polymerase ε (Polε) during mitosis via: (1) tandem Zinc fingers in TTF2 that recognize phosphorylated TRAIP, and (2) a TTF2 motif that directly binds POLE2; this tripartite complex causes TRAIP to ubiquitylate the CMG helicase, triggering mitotic replisome disassembly and MiDAS.\",\n      \"method\": \"Biochemical reconstitution, co-immunoprecipitation, domain mapping (zinc finger mutants, POLE2-binding motif mutants), ubiquitylation assay, mitotic replisome disassembly assay\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reconstituted complex with domain mapping and functional ubiquitylation assay; multiple orthogonal approaches in one study\",\n      \"pmids\": [\"bio_10.1101_2024.12.01.626218\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"GINS4 directly binds POLE2 (predicted by STRING/HDOCK databases and supported by experimental validation); GINS4 knockdown reduces POLE2 expression and inhibits PI3K/AKT signaling via POLE2; POLE2 overexpression reverses the effects of GINS4 silencing on HCC cell proliferation, cycle arrest, and ferroptosis.\",\n      \"method\": \"Co-immunoprecipitation (interaction prediction + experimental), lentiviral knockdown/overexpression, Western blot, flow cytometry, xenograft model\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — binding interaction and rescue epistasis; computational prediction validated experimentally; single lab\",\n      \"pmids\": [\"40081544\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"POLE2 acts upstream of GINS1 in renal cell carcinoma; GINS1 overexpression reverses the inhibitory effects of POLE2 knockdown on proliferation, metastasis, EMT, and autophagy suppression; the POLE2/GINS1 axis inhibits AKT/mTOR-mediated autophagy to promote EMT and lung metastasis.\",\n      \"method\": \"Bioinformatics, lentiviral knockdown/overexpression, rescue experiments, in vitro and in vivo models, Western blot\",\n      \"journal\": \"Apoptosis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — pathway epistasis established by rescue; single lab with in vivo validation\",\n      \"pmids\": [\"41893924\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"POLE2 (the non-catalytic B-subunit of human DNA polymerase ε) serves as a structural and interaction hub at the replication fork: its C-terminal domain acts as an NPF-motif receptor that recruits diverse nuclear partners (including TTF2, WDHD1, DONSON) involved in replication, DNA repair, and transcription regulation; its N-terminal region binds SAP18 to recruit the Sin3/HDAC co-repressor for chromatin remodeling; during mitosis, TTF2 bridges TRAIP to POLE2, directing TRAIP-mediated ubiquitylation of the CMG helicase to trigger replisome disassembly and MiDAS; its transcription is controlled by an Sp1/E2F promoter element and modulated upstream by FOXM1 and the HDAC10/SP1 acetylation axis; in cancer cells, POLE2 promotes proliferation through downstream stabilization of CD44 (via MDM2 inhibition), FOXM1 (via AURKA), and activation of NRF2/GPX4, PI3K/AKT, and Wnt/β-catenin signaling pathways.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"POLE2 encodes the non-catalytic B-subunit of DNA polymerase ε, functioning as a structural scaffold and protein-interaction hub at the replication fork whose transcription is cell-cycle regulated through Sp1/E2F promoter elements and modulated by the HDAC10/SP1 acetylation axis and FOXM1 [PMID:11433027, PMID:37657752, PMID:35173608]. Its C-terminal domain acts as a general NPF-motif receptor that recruits diverse nuclear partners—including TTF2, WDHD1, and DONSON—through a shallow binding pocket defined by residues Y513, E520, and S522, while its N-terminal region binds SAP18 to recruit Sin3/HDAC co-repressor activity for transcriptional repression [PMID:11872158, PMID:bio_10.1101_2025.03.17.643635]. During mitosis, TTF2 bridges TRAIP to POLE2, directing TRAIP-mediated ubiquitylation of the CMG helicase to trigger replisome disassembly and mitosis-specific DNA synthesis (MiDAS) [PMID:bio_10.1101_2024.12.01.626218]. In cancer contexts, POLE2 promotes proliferation through stabilization of FOXM1 via AURKA and of CD44 via MDM2 inhibition, and activates NRF2/GPX4-mediated ferroptosis resistance and PI3K/AKT signaling [PMID:35039475, PMID:38627379, PMID:38070189, PMID:40081544].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"Establishing how POLE2 transcription is cell-cycle regulated resolved the question of how a replication gene is coordinately expressed during S phase: the POLE2 promoter requires an Sp1 element for basal activity and two overlapping E2F sites for full serum-responsive induction, linking POLE2 expression to E2F-pocket protein complexes.\",\n      \"evidence\": \"Luciferase reporter assays, EMSA, and DNase I footprinting of the human POLE2 promoter\",\n      \"pmids\": [\"11433027\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether E2F-mediated regulation is sufficient to explain POLE2 expression in all cell types\",\n        \"No chromatin-level (ChIP) confirmation of E2F occupancy in vivo at the time\"\n      ]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Demonstrating that POLE2's N-terminal region binds SAP18 and recruits HDAC activity revealed a non-replicative, transcription-regulatory function for a polymerase subunit, expanding the functional repertoire of replication machinery components.\",\n      \"evidence\": \"Yeast two-hybrid, co-immunoprecipitation, reporter assays with trichostatin A inhibition in mouse system\",\n      \"pmids\": [\"11872158\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Interaction demonstrated in mouse; not confirmed in human cells\",\n        \"Endogenous target genes repressed by the POLE2–SAP18–Sin3/HDAC complex remain unidentified\",\n        \"No structural detail of the N-terminal SAP18-binding interface\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Placing POLE2 upstream of AURKA-mediated FOXM1 stabilization in glioblastoma established the first cancer-associated signaling axis through which POLE2 promotes tumor growth beyond its replicative role.\",\n      \"evidence\": \"shRNA knockdown, ubiquitination assays, and rescue experiments in glioblastoma cells in vitro and in vivo\",\n      \"pmids\": [\"35039475\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Mechanism by which POLE2 influences AURKA activity is unknown\",\n        \"Not replicated outside glioblastoma\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identifying FOXM1 as a direct transcriptional regulator of POLE2 expression created a potential FOXM1→POLE2→AURKA→FOXM1 feedback loop, though these findings come from separate cancer types.\",\n      \"evidence\": \"FOXM1 overexpression/knockdown with qRT-PCR and Western blot in lung adenocarcinoma cells\",\n      \"pmids\": [\"35173608\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Direct promoter binding by FOXM1 not shown by ChIP\",\n        \"Whether a true feedback loop operates in any single cell type is untested\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Demonstrating that HDAC10 deacetylates SP1 to maintain SP1 binding at the POLE2 promoter connected epigenetic regulation to POLE2 expression and DNA damage repair, providing an upstream regulatory layer.\",\n      \"evidence\": \"shRNA knockdown, acetylation assay, ChIP, overexpression rescue, DNA damage assays in NSCLC cells\",\n      \"pmids\": [\"37657752\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether SP1 acetylation status affects POLE2 expression in non-cancer contexts is unknown\",\n        \"Specific acetylation sites on SP1 not mapped\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showing that POLE2 activates NRF2/GPX4 signaling to suppress ferroptosis in gastric cancer revealed a non-canonical role for POLE2 in regulating oxidative stress and cell death.\",\n      \"evidence\": \"Overexpression/knockdown, ferroptosis assays, rescue with NRF2/GPX4 silencing in gastric cancer cells\",\n      \"pmids\": [\"38070189\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"How POLE2, a replication factor, mechanistically upregulates NRF2 transcription or stability is unresolved\",\n        \"Single cancer type; no normal-tissue comparison\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Establishing that POLE2 stabilizes CD44 by reducing MDM2-mediated ubiquitination linked POLE2 to Rac signaling and osteosarcoma progression, showing POLE2 can modulate specific E3 ligase–substrate interactions.\",\n      \"evidence\": \"Ubiquitination assay, rescue epistasis with CD44 knockdown, in vitro and in vivo osteosarcoma models\",\n      \"pmids\": [\"38627379\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether POLE2 directly interacts with MDM2 or CD44, or acts indirectly, is undetermined\",\n        \"Mechanism of MDM2 inhibition by POLE2 not established\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Reconstitution of the TTF2–TRAIP–POLE2 tripartite complex during mitosis answered how the TRAIP ubiquitin ligase is targeted to the replisome: TTF2 bridges phosphorylated TRAIP to POLE2, directing CMG helicase ubiquitylation for replisome disassembly and MiDAS.\",\n      \"evidence\": \"Biochemical reconstitution, domain mapping with zinc-finger and POLE2-binding-motif mutants, ubiquitylation assay (preprint)\",\n      \"pmids\": [\"bio_10.1101_2024.12.01.626218\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Awaits peer-reviewed publication\",\n        \"In vivo validation of TTF2-POLE2 interaction requirements for MiDAS not yet shown in mammalian cells\",\n        \"Whether other NPF-containing partners compete with TTF2 for POLE2 binding during mitosis is unknown\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identifying POLE2's C-terminal pocket as a general NPF-motif receptor that binds multiple nuclear partners (TTF2, WDHD1, DONSON, SYNJ1) resolved the structural basis of POLE2's role as a protein-interaction hub at the replication fork.\",\n      \"evidence\": \"Native holdup assay, quantitative binding measurements, mutagenesis of Y513/E520/S522, AlphaFold modeling, proteome-scale screen (preprint)\",\n      \"pmids\": [\"bio_10.1101_2025.03.17.643635\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Awaits peer-reviewed publication\",\n        \"Crystal or cryo-EM structure of the NPF-POLE2 complex not yet available\",\n        \"Functional consequences of individual NPF-partner recruitment at the fork remain to be dissected\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Demonstrating that GINS4 binds POLE2 and signals through PI3K/AKT extended the replication-complex interactome of POLE2 and linked it to a growth-signaling pathway in hepatocellular carcinoma.\",\n      \"evidence\": \"Co-immunoprecipitation, lentiviral knockdown/overexpression rescue, Western blot, xenograft model in HCC\",\n      \"pmids\": [\"40081544\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"GINS4–POLE2 interaction initially predicted computationally; single reciprocal Co-IP\",\n        \"Whether PI3K/AKT activation is a direct or indirect consequence of the GINS4–POLE2 axis is unknown\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include how POLE2's NPF-motif receptor function is regulated during the cell cycle (partner switching), how POLE2 influences signaling pathways (NRF2, PI3K/AKT, Wnt) outside its replication role, and whether the non-replicative cancer phenotypes reflect physiological functions or neomorphic activities.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No structural determination of the full-length POLE2 in complex with Pol ε holoenzyme and NPF partners\",\n        \"Mechanism connecting POLE2 to transcription factor or E3 ligase regulation remains indirect in all cancer studies\",\n        \"Whether POLE2's NPF-binding and SAP18-binding functions are coordinated or mutually exclusive is untested\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [8, 9]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [8, 9]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 8, 9]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-69306\", \"supporting_discovery_ids\": [8, 9]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [1, 9]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [6]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"complexes\": [\n      \"DNA polymerase ε holoenzyme\",\n      \"TTF2–TRAIP–POLE2 complex\",\n      \"SAP18–Sin3/HDAC complex\"\n    ],\n    \"partners\": [\n      \"SAP18\",\n      \"TTF2\",\n      \"TRAIP\",\n      \"WDHD1\",\n      \"DONSON\",\n      \"GINS4\",\n      \"FOXM1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}